Please ensure Javascript is enabled for purposes of website accessibility

FDA Approves Sanofi's Multiple Myeloma Drug

By Mark Prvulovic - Mar 3, 2020 at 4:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Patients with this rare blood cancer have another treatment option available to them.

The U.S. Food and Drug Administration (FDA) announced that it has approved Sanofi's (SNY -5.01%) new drug for patients with reoccurring multiple myeloma. Sarclisa (also known as isatuximab) is a treatment that promotes tumor cell death by targeting a specific protein type found on the surface of white blood cells.

The agency approved Sarclisa to be used as a drug combo alongside Bristol-Myers Squibb's Pomalyst (also known as pomalidomide) and a steroid medication known as dexamethasone. Adult patients who have had at least two previous treatments for multiple myeloma but have had the condition return are eligible for this treatment.

An FDA stamp beside two pill packets.

Image source: Getty Images.

"While there is no cure for multiple myeloma, Sarclisa is now another CD38-directed treatment option added to the list of FDA-approved treatments of patients with multiple myeloma who have progressive disease after previous therapies," said Richard Pazdur, director of the Oncology Center of Excellence at the FDA. "In the clinical trial, there was a 40% reduction in the risk of disease progression or death with this therapy."

Further details

Multiple myeloma is a type of blood cancer that forms within a specific type of white blood cell known as a plasma cell. These cancerous plasma cells end up accumulating in the bone marrow, where they crowd out healthy blood cells. While there are treatments available to kill these myeloma cells, the chance of relapse is very high, with almost all cases of multiple myeloma leading to an eventual return of the disease.

Sanofi isn't the only pharmaceutical giant working on developing a multiple myeloma treatment. Johnson & Johnson recently submitted its own treatment, Darzalax, for FDA approval earlier in February.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$50.03 (-5.01%) $-2.64
Johnson & Johnson Stock Quote
Johnson & Johnson
$177.51 (0.29%) $0.52
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$77.00 (-0.95%) $0.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.